aSwitching period refers to the participants started on teriflunomide and not applicable to the participants on ofatumumab in the core period. For the teriflunomide/ofatumumab group, data from the first dose of teriflunomide until the last dose of ofatumumab plus 100 days or analysis cutoff date has been used. R1: The first participant with first treatment-emergent assessment in ofatumumab period after switching to ofatumumab (72 weeks); R2: The last participant with last treatment-emergent assessment in teriflunomide period before switching to ofatumumab (120 weeks). For all pooled analyses, a fixed value of LLN (using ALITHIOS study reference) was used: IgG: 5.65 g/L and IgM: 0.4 g/L.
Longer-Term Safety and Efficacy of Ofatumumab in People With Relapsing Multiple Sclerosis for Up to 6 Years Wiendl H, et al. AAN 2024. P9.010 |
|---|
| Mean serum IgG levels remained stable and above the LLN (5.65 g/L) throughout the entire treatment period in both groups and in the majority of the patients (97.2%). Mean serum levels of IgM decreased in both groups, but in the majority of patients (65.9%), IgM levels remained above the LLN (0.40 g/L) |
Ig, Immunoglobulin
